GILD vs NVS
GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | GILD | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $130.21 | $156.11 | |
| Market cap as of 2026-08-03 | $161.7B | $232.1B | |
| P/E as of 2026-08-03 | 17.71 | 22.53 | GILD lower |
| PEG as of 2026-08-03 | 2.53 | 3.66 | GILD lower |
| Net margin as of 2026-08-03 | +31.0% | +22.5% | GILD higher |
| Gross margin as of 2026-08-03 | +79.3% | +75.0% | GILD higher |
| Operating margin as of 2026-08-03 | +34.9% | +29.9% | GILD higher |
| ROE as of 2026-08-03 | +42.2% | +29.9% | GILD higher |
| ROA as of 2026-08-03 | +16.1% | +11.1% | GILD higher |
| Debt / equity as of 2026-08-03 | 0.94 | 1.18 | GILD lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.5% | +3.3% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | n/a | |
| Dividend yield as of 2026-08-03 | +2.5% | +2.9% | NVS higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.32 | 1.17 | |
| 1-year return as of 2026-07-31 close | +16.0% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.